A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

Inclusion Criteria:

• Signed informed consent must be obtained prior to participation in the study.

• Age 18-45 years

• Diagnosis of RRMS per McDonald Criteria (2017)

• EDSS 0-5.5 (Inclusive)

• Able to obtain MRI and attend study visits at sites

• Willing to use wearable device as specified in the protocol

• Able to provide blood sample

• On a current DMT with approved label use for treatment of RRMS at least 6 monthsprior to Screening

• No relapse reported within 6 months prior to Screening

• Patients may enroll in the trial if they have subclinical disease activity asmeasured by MRI prior to enrollment. An absence of MRI activity is not exclusionary.

Exclusion Criteria:

• Primary progressive or secondary progressive phenotype

• Diseases other than multiple sclerosis responsible for the clinical or MRIpresentation

• Use of experimental or investigational drugs for MS within 2 years from Screening

• Known sensitivity to gadolinium

• Central Nervous System (CNS) anomalies that are better accounted for by anotherdisease process

• Known active malignancies

• Active chronic disease (or stable but treated with immune therapy) of the immunesystem other than MS

• Active infections including systemic bacterial, viral (including COVID-19) or fungalinfections, known to have AIDS or tested positive for HIV antibodies

• Neurological findings consistent with Progressive Multifocal Leukoencephalopathy (PML), or confirmed PML

• IgG or IgM levels below lower limit of normal (LLN) at Screening